13/09/2017 22:32:26

CrownBio’s Integrated Oncology Platform Helps Advance Apogenix’s Promising HERA-GITRL Immunotherapy for NSCLC and Head and Neck Cancer

SANTA CLARA, Calif., 2017-09-13 23:32 CEST (GLOBE NEWSWIRE) --

Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces that their integrated oncology platform has facilitated the preclinical development of a HERA-GITRL immunotherapeutic from Apogenix. HERA-GITRL is an immunotherapy showing antitumor activity in Non-Small Cell Lung Cancer (NSCLC) and Head and Neck Cancer.

The data derived from studies using CrownBio’s portfolio were first presented by Apogenix in an oral presentation at the AACR 2017 Annual Meeting. These data showed the immunotherapy’s potential clinical utility and demonstrated the benefits of using CrownBio’s platform in preclinical efficacy testing.

“CrownBio’s integrated oncology platform confirmed our agent’s efficacy in NSCLC and head and neck cancers,” said Dr. Mauricio Redondo Müller, Director, Preclinical Development at Apogenix. “The scientific expertise, predictive tools, and well-validated models CrownBio provides gave us the data we needed to progress our HERA-GITRL immunotherapy to the next stage.”

“It is our mission to deliver innovative technologies so that companies like Apogenix can leverage and accelerate their research,” said Laurie Heilmann, SVP of Global Strategy, Marketing & Business Development. “Our scientific oncology platform uniquely enhances preclinical immunotherapy development and will continue to deliver valuable insights that drive new discoveries in this area.”

About Crown Bioscience Inc.

Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.

About Apogenix

Apogenix develops innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in fall 2005, Apogenix has raised more than 100 million euros in financing rounds, public grants, and upfront payments from licensing agreements. The company is based in Heidelberg, Germany.

         Media Enquiries:

         

         Jody Barbeau

         

         Crown Bioscience Inc. marketing@crownbio.com

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
18 Feb
NOVO-B
Når ens hustru har lidt voldsomt under diabetes  og dens bivirkninger tiltagende gennem 25 år, så er..
34
19 Feb
 
Jeg tager hatten for dit velbegrunede og fyldestgørende indlæg til debatten. Det kunne mange lære af..
32
21 Feb
GEN
Det er altid rart at møde et ungt menneske, der har potentiale til at blive klogere.
26
23 Feb
ZEAL
Jeg har tildigere her på EI rapporteret at Soliqua ville blive lanceret i Sydkorea. Nu har Sanofi af..
25
21 Feb
GEN
Du bliver da dummere og dummere at høre på 
21
24 Feb
NRDF
  Aktieugen er overstået og desværre, men ikke særligt overraskende, viste det sig igen, at det dans..
15
23 Feb
ZEAL
Sanofi og  har for et par dage siden oplyst på clinicaltrial.gov at de starter studiet «LixiPark» me..
14
23 Feb
GEN
H2 2018 er pakket med nyheder og kliniske data fra daratumumab i solide tumorer er en af de største ..
12
21 Feb
TRMD-A
Mange års erfaring i teknisk analyse berettiger mig til at give dig følgende svar:    Torm viser akt..
12
20 Feb
 
Helt korrekt. Jeg skiftede job i 2007 og har på denne ene pension fra dette tidspunkt indbetalt 648...
12

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
Pomerantz Law Firm Announces the Filing of a Class Action against Bellicum Pharmaceuticals, Inc. and Certain Officers – BLCM
2
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in MetLife, Inc. of Class Action Lawsuit and Upcoming Deadline – MET
3
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Super Micro Computer, Inc. of Class Action Lawsuit and Upcoming Deadline – SMCI
4
Canada’s Johnston Maintains Lead after Day Three of FLW Tour at Harris Chain of Lakes Presented by Lowrance
5
PRF: Consolidated Unaudited Interim Report of AS PRFoods for 4th quarter and 12 months of 2017

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 February 2018 09:42:49
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: ReleaseBuild_20180222.1 - EUROWEB1 - 2018-02-25 10:42:49 - 2018-02-25 09:42:49 - 1000 - Website: OKAY